Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): A population-based study, 1993-2007

Leukemia Research

Volumn 36, Issue 10, 2012, Pages 1262-1266

  Osca Gelis, Gemma ^a,b,c   Puig Vives, Montserrat ^a,b,c   Saez, Marc ^b,c   Gallardo, David ^d   Solé, Francesc ^e   Marcos Gragera, Rafael ^a,b,c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

Chronic myelomonocytic leukemia; Incidence rate; Population based cancer registry; Relative and observed survival

Indexed keywords

ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVED SURVIVAL; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; RELATIVE SURVIVAL; SEX DIFFERENCE; SPAIN; SURVIVAL; TREND STUDY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; REGISTRIES; SPAIN; SURVIVAL RATE; TIME FACTORS;

EID: 84865178102     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.06.009     Document Type: Article

References (28)

1. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001, IARC Press, Lyon. E.S. Jaffe, E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
2. Emanuel P.D. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008, 22(July (7)):1335-1342.
3. Germing U., Gattermann N., Minning H., Heyll A., Aul C. Problems in the classification of CMML - dysplastic versus proliferative type. Leuk Res 1998, 22(October (10)):871-878.
4. Orazi A., Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008, 22(July (7)):1308-1319.
5. Sabattini E., Bacci F., Sagramoso C., Pileri S.A. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010, 102(June (3)):83-87.
6. Elliott M.A. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Pract Res Clin Haematol 2006, 19(3):571-593.
7. Cazzola M. Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica 2011, 96(March (3)):349-352.
8. Germing U., Kundgen A., Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004, 45(July (7)):1311-1318.
9. Kosmider O., Gelsi-Boyer V., Ciudad M., Racoeur C., Jooste V., Vey N., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94(December (12)):1676-1681.
10. Mallo M., Osca G., Solorzano J., Arenillas L., Florensa L., Sole F. TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica 2010, 95(October (10)):1798-1800.
11. Reiter A., Invernizzi R., Cross N.C., Cazzola M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica 2009, 94(December (12)):1634-1638.
12. Such E., Cervera J., Costa D., Sole F., Vallespi T., Luno E., et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011, 96(March (3)):375-383.
13. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(July (5)):937-951.
14. World Health Organization International classification of diseases for oncology 2000, World Health Organization, Geneva, Switzerland. 3rd ed.
15. Jaffe E.S., Harris N.L., Diebold J., Muller-Hermelink H.K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999, 111(January (1 Suppl. 1)):S8-S12.
16. Sant M., Allemani C., Tereanu C., de A.R., Capocaccia R., Visser O., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116(November (19)):3724-3734.
17. Bauduer F., Ducout L., Dastugue N., Capdupuy C., Renoux M. Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res 1998, 22(March (3)):205-208.
18. Gologan R., Georgescu D., Tatic A., Radulescu I., Vasilache D. Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania. Leuk Res 2009, 33(November (11)):1556-1561.
19. Intragumtornchai T., Prayoonwiwat W., Swasdikul D., Suwanwela N., Chaimongkol B., Jootar S., et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998, 22(May (5)):453-460.
20. Maynadie M., Verret C., Moskovtchenko P., Mugneret F., Petrella T., Caillot D., et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996, 74(July (2)):288-290.
21. Maynadie M., Girodon F., Manivet-Janoray I., Mounier M., Mugneret F., Bailly F., et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica 2011, 96(January (1)):55-61.
22. Phekoo K.J., Richards M.A., Moller H., Schey S.A. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006, 91(October (10)):1400-1404.
23. Neukirchen J., Schoonen W.M., Strupp C., Gattermann N., Aul C., Haas R., et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res 2011, 35(December (12)):1591-1596.
24. Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112(July (1)):45-52.
25. Beran M., Wen S., Shen Y., Onida F., Jelinek J., Cortes J., et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007, 48(June (6)):1150-1160.
26. Elliott M.A., Tefferi A., Hogan W.J., Letendre L., Gastineau D.A., Ansell S.M., et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006, 37(June (11)):1003-1008.
27. Germing U., Strupp C., Knipp S., Kuendgen A., Giagounidis A., Hildebrandt B., et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 2007, 92(July (7)):974-977.
28. Costa R., Abdulhaq H., Haq B., Shadduck R.K., Latsko J., Zenati M., et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011, 117(June (12)):2690-2696.